PCN104 Cost-Utility MODEL of Trastuzumab Emtansine (T-DM1) in HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab and a Taxane, Compared with Capecitabine PLUS Lapatinib, Trastuzumab ...
Abstract
Authors
B. Akyol Ersoy E. Erdogan-Ciftci L. Yanik B. Guler G. Ozcan N. Paracha